Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 1
Sponsor overview
Samsung Medical Center
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT01091207 | https://clinicaltrials.gov/study/NCT00609804 | https://clinicaltrials.gov/study/NCT01004003 | https://clinicaltrials.gov/study/NCT02084732 | https://clinicaltrials.gov/study/NCT03166176
Assets
Linked programs
- Sorafenib: Results Not Found Signal (3/5)
- Vistusertib(AZD2014): Registry Stop Signal (4/5)